Introduction
While thymopoiesis is critical for generating peripheral T cells in infants and in children, it is thought to play a minimal role during adult T cell homeostasis (1) (2) (3) (4) (5) . Under steady state conditions, constant levels of T cells in the periphery are maintained mainly through homeostatic proliferation (4) (5) (6) . Depletion of the vast majority of peripheral T cells through irradiation, chemotherapy, or lymphocyte-depleting reagents or during some infections or neurological injuries disrupts T cell maintenance (7) (8) (9) (10) (11) . For the organism to reach predepletion T cell levels, the resulting lymphopenia triggers homeostatic proliferation through several mechanisms distinct in the requirements for specific antigen recognition, cytokines, and costimulatory pathways (12) . Human studies show that in addition to enhanced homeostatic proliferation, the thymus increases in size and gives rise to recent thymic emigrants during acute lymphopenia (6, 7, (13) (14) (15) (16) (17) . These findings suggest that the thymus may have an important function of balancing T cell numbers in lymphopenic adults, but this possibility has not been directly tested in animal models of lymphopenia.
Different mechanisms of T cell reconstitution after lympopenia may skew the proportion of various T cell subsets and the diversity of the T cell repertoire, which, in turn, determines the ability of the host to respond to future immunologic challenges. Understanding the mechanisms driving lymphocyte repopulation after lymphopenia is an important issue in the fields of transplant immunology and autoimmunity. It is acknowledged that preexisting alloreactive or autoreactive memory T cells are less susceptible to depletion, thus undermining the efficacy of lymphoablative therapies (18) (19) (20) (21) . A seminal study by Pearl et al demonstrated that memory T cell subsets surviving lymphoablative induction therapies in renal transplant recipients are prevalent at the time of rejection (22) . In addition, rapid homeostatic proliferation of memory T cells after lymphoablation may increase the numbers of pathogenic T cells and worsen disease outcome. To date, there are several unresolved questions with regard to T cell reconstitution after depletion. First, the relative contributions of peripheral T cell homeostatic proliferation versus thymopoiesis to T cell repertoire recovery are unknown. Second, the possible links between peripheral T cell recovery and increased thymopoiesis under lymphopenic conditions have not been explored. Studying such mechanisms will potentially allow manipulating the host T cell repertoire by targeting the rates of homeostatic proliferation versus thymopoiesis.
We have previously shown that the treatment of mice with murine anti-thymocyte (mATG) spares a population of CD44 hi effector/memory CD4 T cells and that these residual CD4 T cells are necessary for the recovery of CD8 T cells to predepletion levels (18) . Several reports from different fields suggest the potential importance of peripheral memory CD4 T cells in thymic function (14) (15) (16) 23) . For example, the presence of CD4 T cells within the bone marrow or hematopoietic stem cell preparations correlates with better rate of thymopoiesis in bone marrow transplant recipients (14, 23) . In addition, animal studies showed that T cells can traffic from the periphery into the thymus and influence positive and negative thymocyte selection (24) (25) (26) (27) (28) (29) . However, the mechanisms and consequences of such recirculation are still poorly understood and have not been examined under lymphopenic conditions.
The goal of the current study was to investigate the contribution of the thymus to T cell reconstitution after mATG depletion in heart allograft recipients and the role of residual memory CD4 T cells as a potential link between homeostatic proliferation and thymopoiesis. We report that T cell reconstitution after mATG depletion is severely impaired in thymectomized heart allograft recipients, leading to extended heart allograft survival compared with euthymic mATG-treated recipients. Most importantly, our findings indicate that depletion-resistant memory CD4 T cells migrate into the thymus and that manipulating the numbers of peripheral memory CD4 T cells alters thymopoiesis in lymphopenic recipients. This is the first demonstration that peripheral T cells may influence thymic maturation and output during lymphopenia, thus promoting rapid recovery of lymphocyte homeostasis. 
Materials and Methods

Animals
Surgical procedures
B6 or B6.RAG1 À/À mice received thymectomy at the Jackson Laboratories facility between ages of 5 and 6 weeks. Mice were then rested for 1 week before shipment and used in the study between 1 and 11 weeks postthymectomy. Vascularized heterotopic cardiac transplantation was performed as previously described (30, 31) . Graft rejection was defined as complete loss of palpable heartbeat and confirmed by laparotomy. Thymus transplantation under the kidney capsule (32) was performed simultaneously with heterotopic heart transplantation to minimize surgical stress. The 3-to 5-week-old donor B6 or B6.RAG1 À/À mice were killed, and thymi were carefully removed to preserve the organ structure. Thymi were then washed in Ringer's solution and placed under the kidney capsule of anesthetized B6 thymectomized mice prior to performing the heart transplantation. In our experiments, one wild-type (WT) thymus was divided in half and transplanted into two recipients, while one RAG1 À/À thymus was transplanted into one recipient due to the sizes of the thymi.
Recipient treatment
Rabbit anti-mouse thymocyte serum was generated by the Hybridoma Core at the Cleveland Clinic Lerner Research Institute by immunizing rabbits with C3H, DBA1, and SJL thymocytes. Total IgG (mATG) was isolated via a sequential ammonium sulfate precipitation. Total protein concentration was measured by using BCA assay (Thermo Fisher Scientific, Waltham, MA), and the purity was confirmed by SDS-PAGE. Heart allograft recipients were treated with mATG (1 mg i.p.) or control rabbit IgG (Equitech-Bio Inc., Kerrville, TX) on days 0 and 4 posttransplantation.
Agonistic anti-CD40 mAb (clone FGK4.5; BioXcell, West Lebanon, NH) was injected into recipients on days 0 and 1 post-heart transplantation (100 lg i.v.) Depleting anti-mouse CD4 mAb (clones GK1.5 and YTS191; BioXCell) were injected on days À3, À2, and À1 relative to heart transplantation and mATG treatment (200 lg i.p.)
T cell isolation and transfer
Na€ ıve B6 or CD45.1 B6 mice were killed, and spleens and peripheral lymph nodes (inguinal, mesenteric, axial, and brachial) were pooled. Single-cell suspensions were generated, and CD4 T cells were isolated by using mouse negative selection isolation kits from Stem Cell Technologies (Vancouver, BC, Canada) according to the manufacturer's instructions. T cells were counted and 13-19 9 10 6 CD4 T cells were injected intravenously into thymectomized mice. In other experiments, CD4, CD8, or total CD3 + T cells were isolated from pooled spleens and lymph nodes of naive B6 mice, labeled with carboxyfluorescein diacetate, succinimidyl ester (CFSE), and injected intravenously into thymectomized or euthymic RAG1 À/À mice at 3 9 10 6 isolated CD4 or CD8 T cells or 10 9 10 6 total T cells per recipient. The proliferation of transferred T cells was analyzed in the spleen by using CFSE dilution.
CFSE labeling
Isolated CD4, CD8, or total spleen T cells were labeled with CFSE as previously published (33) . Briefly, cells were resuspended at 10 9 10 6 /mL in PBS supplemented with 0.1% BSA and incubated with 1.25 lmol/L CFSE for 10 min at 37°C. The staining was stopped via the addition of an equal volume of fetal calf serum (FCS; Atlanta Biologicals, Lawrenceville, GA). Cells were then washed twice with RPMI 1640 (Gibco Life Technologies, Grand Island, NY) supplemented with 10% FCS, counted, and used for adoptive transfer experiments.
ELISPOT assays
Interferon (IFN)ɣ ELISPOT assays were performed as previously described using capture and detection anti-mouse IFNɣ antibodies from BD Biosciences (San Diego, CA) (31) . Recipient spleen cells were stimulated with mitomycin C-treated BALB/c or SJL spleen cells for 16-24 h. Spots were developed and analyzed by using an ImmunoSpot Series 4 analyzer (Cellular Technology, Shaker Heights, OH).
Flow cytometry
The following conjugated antibodies were purchased from BD Biosciences or eBioscience (San Diego, CA): fluorescein isothiocyanate
phycoerythrin (PE)-anti-CD45.2 (clone 104), PE-Cy7-anti-CD4 (clones GK1.5 and RM4-5), Texas Red (TR)-anti-CD25 (PC61), TR-anti-CD24 (M1.69), allophycocyanin (APC)-anti-CD8a (53-6.7), and APC-Cy7-anti-CD44 (IM7). Cells were stained as previously described (34, 35) . At least 200 000 events per sample were acquired on a BD Biosciences LSRII and analyzed by using FlowJo software (Tree Star, Ashland, OR).
Measurement of serum alloantibody titers
Donor-and third party-reactive IgG1, IgG2c, IgG2b, and IgG3 antibody titers were determined as previously published (36) . Donor BALB/c and third party SJL thymocytes were incubated with serially diluted recipient serum followed by fluorochrome-labeled anti-mouse IgG1, IgG2c, IgG2b, and IgG3 antibodies (all from BD Biosciences). Cells were washed and analyzed by flow cytometry. The serum dilution that returned the mean fluorescence intensity (MFI) to the level observed after staining with na€ ıve B6 serum was divided by 2 and reported as the titer.
Statistical analysis
Heart allograft survival was compared between recipient groups by using Kaplan-Meier analysis. All other results were analyzed by using a onetailed Student t-test. The difference between groups was considered to be significant if the p value was <0.05. Unless noted otherwise, the data are presented as mean AE SD values. Total numbers of animals in each experimental group are indicated in respective figure legends.
Results
The thymus is required for rapid reconstitution of T cells following mATG depletion
To investigate the role of the thymus during T cell reconstitution following lymphoablation, we compared the rates of T cell reconstitution in mATG-treated thymectomized and euthymic recipients of fully MHC-mismatched cardiac allografts ( Figures 1A-D) . To account for natural decline of T cell numbers in thymectomized mice during the course of the experiment, we used age-matched undepleted thymectomized heart allograft recipients as controls (Figures 1E and F) . We observed similar levels of CD8 T cell depletion on day 7 posttransplantation in thymectomized and euthymic recipients treated with mATG. However, the recovery of CD8 T cells was severely impaired in the absence of the thymus (Figures 1B and E). It took >100 days after transplantation for CD8 T cells to reach predepletion levels observed in nondepleted thymectomized recipients ( Figure 1E ). Notably, euthymic and thymectomized mice had comparable numbers of peripheral blood cells before and at different time points after transplantation ( Figure 1D ), indicating that the decreased proportions of lymphocytes in thymectomized recipients reflect a decrease in absolute cell numbers. Before depletion, thymectomized mice had a significant reduction in CD4 T cell numbers compared with age-matched euthymic mice ( Figure 1C ). Regardless of predepletion frequencies, CD4 T cell depletion rates on day 7 posttransplantation were similar in thymectomized and euthymic recipients. However, thymectomy severely impaired CD4 T cell recovery compared with that observed in euthymic recipients ( Figure 1C ). These data demonstrate that rapid CD4 and CD8 T cell reconstitution after lymphoablation is dependent on the presence of a functional thymus.
Consistent with the delay in T cell reconstitution, mATGtreated thymectomized recipients demonstrated significantly reduced donor-specific T cell responses and prolonged heart allograft survival compared with euthymic recipients ( Figures 1G and H) . Despite the decrease in total and alloreactive T cells, mATG-treated thymectomized recipients developed donor-specific IgG alloantibodies (DSAs), indicating that remaining peripheral CD4 T cells were sufficient to provide help for alloreactive B cells and suggesting that DSAs contribute to the allograft rejection in this model ( Figure 1I ). It should be noted that thymectomy procedure alone did not compromise donorspecific alloreactivity as untreated thymectomized and euthymic mice had similar kinetics of heart allograft rejection and comparable donor-specific IFNc production by spleen T cells at the time of rejection ( Figures 1G and H ).
CD4 T cell numbers are reduced after thymectomy in na€ ıve nontransplanted mice Because thymectomized recipients had lower predepletion levels of circulating CD4 T cells ( Figure 1C ), we next investigated how thymectomy affects CD4 and CD8 T lymphocyte subsets in na€ ıve nontransplanted mice. We found a significant decrease in numbers of CD4 T cells in the peripheral blood, spleens, and lymph nodes of thymectomized mice analyzed between 1 and 11 weeks after thymectomy in comparison to age-matched euthymic controls (Figures 2A-C) . The decrease in CD4 T cell compartment did not correlate with animal age or time elapsed after thymectomy procedure (data not shown).
Although the absolute numbers of CD8 T cells were significantly decreased in the spleen and lymph nodes of thymectomized mice in comparison to euthymic mice, the overall decrease in CD3 + T cells was mainly due to the reduced CD4 T cell subset. Notably, thymectomized animals had significantly increased proportions of effector/memory CD44 hi T cells within both CD4 and CD8 populations ( Figure 2D ). CD4 T cell transfer, treatment with agonistic anti-CD40 antibody, or thymus transplantation only partially restore T cell reconstitution in thymectomized mice We next asked if decreased numbers of peripheral CD4 T cells in thymectomized mice before depletion may account for impaired CD8 T cell reconstitution and whether the transfer of additional CD4 T cells into thymectomized mice before mATG depletion facilitates CD4 and CD8 T cell recovery ( Figure 3A, top) . Injection of 10 9 10 6 CD4 T cells isolated from na€ ıve B6 mice improved both CD8 and CD4 T cell reconstitution after mATG depletion ( Figures 3B and C) . In our previous studies in euthymic mice, depletionresistant CD4 T cells mediated homeostatic proliferation of CD8 T cells in an CD40/CD154-dependent manner (18) . Consistent with our previous findings, injection of agonistic anti-CD40 mAb at the time of mATG depletion ( Figure 3A , bottom) accelerated the recovery of CD8 and CD4 T cells after mATG treatment (Figures 3D and E) . Notably, neither CD4 T cell transfer nor CD40 mAb injection supported further T cell reconstitution to the levels observed in euthymic recipients, demonstrating that the thymus is critical under these conditions. Furthermore, the survival of allografts in thymectomized recipients was not significantly affected by either treatment compared with mice treated with mATG alone ( Figure 3F ).
We next tested whether thymus transplantation restores the defective T cell recovery in mATG-treated thymectomized mice ( Figure 4A ). The transplantation of either RAG1 À/À or WT thymus under the kidney capsule significantly enhanced both CD8 and CD4 T cell reconstitution after mATG treatment (Figures 4B-E) and accelerated heart allograft rejection in the majority of the recipients ( Figure 4F ) compared with thymectomized recipients treated with mATG without thymus transplantation. While thymus transplantation resulted in a steady increase in peripheral CD4 and CD8 T cells, the T cell numbers were markedly lower than those in mATG-depleted euthymic recipients at all analyzed time points. Taken together, these results further confirm that both peripheral CD4 T cells and the thymus are necessary for optimal T cell reconstitution after mATG depletion.
Peripheral CD4 T cells migrate into the thymus and enhance thymopoiesis in lymphopenic mice
Our data indicate that either thymus transplantation or transfer of peripheral CD4 T cells can enhance the rate of T cell reconstitution after lymphoablation in thymectomized mice. To test potential cooperation between the thymus and peripheral CD4 T cells after mATG treatment, we injected congenic B6.CD45.1 + CD4 T cells into B6.CD45.2 + thymectomized mice before the transplantation of (CD45.1 9 CD45.2 F1) thymus and BALB/c heart allograft and mATG depletion ( Figure 5A ). This design allowed separate analyses of transferred CD4 T cells, recipient T cells, and T cells generated by the donor thymus from passenger precursors. Transferred CD4 T cells were detectable in the transplanted thymus on day 15 posttransplantation (Figures 5B and  C) . Expression of CD24 and Qa2 cell surface markers is commonly used to define a population of mature lymphocytes reentering the thymus from the periphery (Qa2 hi C-D24 lo SP cells) (37) . Along with the infiltration of transferred CD4 T cells, we observed increased numbers 
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Figure 3: CD4 T cell transfer or treatment with agonistic anti CD40 antibody facilitates T cell reconstitution in thymectomized heart allograft recipients. (A) Thymectomized B6 mice were transplanted with BALB/c heart allografts and treated with murine anti-thymocyte globulin on days 0 and 4 posttransplantation. One group of recipients was injected with 10 9 10 6 CD4 T cells isolated from na€ ıve B6 mice 1 day before heart transplantation (top). Another group was injected with agonistic anti-CD40 mAb (clone FGK4.5, 100 µg i.v.) on days 0 and 1 after heart transplantation (bottom). (B and C) CD8 (B) and CD4 (C) T cell recovery in the peripheral blood of recipients injected with CD4 T cells. Data are shown as mean AE SD, n = 10-14 mice/group pooled from three independent experiments. (D and E) CD8 (D) and CD4 (E) T cell recovery in the peripheral blood of recipients injected with anti-CD40 mAb. Data are shown as mean AE SD, n = 6-10 mice/group. (H) Heart allograft survival; n = 10-11 mice/group: ns, p > 0.05, *p < 0.05, **p < 0.001, ***p < 0.0001. of host-derived Qa2 hi CD24 lo SP CD4 cells in transplanted thymi consistent with the enhanced mature lymphocyte recirculation to the thymus in these recipients (Figure 5D ).
Presence of recirculating mature CD4 T cells in the thymus was associated with the increased thymic size and thymic cellularity ( Figure 6A ). Recipients injected with CD4 T cells had increased numbers of both hostderived CD45.1 + (DP) to single-positive (SP) CD4 or CD8 cells ( Figure 6E ). The similar increase was observed at all stages in host cells, with differences in DN and SP CD4 cells being statistically significant ( Figure 6C ). These results indicate that transferred CD4 T cells influence host thymopoiesis as early as at DN1 thymocyte development stage.
Even though spleen cell numbers were similar between the two groups ( Figure 6F ), mice that received CD4 T cells and the thymus transplantation exhibited significantly lower anti-donor T cell responses in comparison to mice that did not receive CD4 T cells, as measured by donor antigen-specific IFNc production ( Figure 6G ). These findings are consistent with the hypothesis that transferred CD4 T cells enhance thymopoiesis and thus increase the proportion of antigen-unexperienced thymic emigrants over homeostatically expanding alloreactive T cells.
Peripheral CD4 T cells facilitate two distinct stages of thymopoiesis after mATG lymphoablation
We previously demonstrated that depletion-resistant peripheral CD4 T cells are critical for the reconstitution of CD8 T cell compartment after mATG depletion (18) . To test if residual CD4 T cells also affect the process of thymopoiesis in lymphopenic mice, we treated B6 mice with depleting anti-CD4 mAbs before BALB/c heart allograft transplantation and mATG treatment. On day 6 posttransplantation, the numbers of DN, DP, or SP CD4 and CD8 cells in the thymus were comparable between CD4-depleted and control heart allograft recipients ( Figure 7A À/À thymus. Data are shown as mean AE SD, n = 5-11 mice/group. (F) Heart allograft survival; n = 6-11 mice/group: ns, p > 0.05; *p < 0.05; **p < 0.001; ***p < 0.0001. addition to mATG treatment had significantly reduced populations of DN and SP CD4, but not of DP or SP CD8 thymocytes ( Figure 7A, bottom) . Further analysis of DN subsets based on CD44 and CD25 expression revealed that CD4 depletion decreased the numbers of DN cells from DN2 stage onward, suggesting that peripheral CD4 T cells facilitate DN1-to-DN2 transition and/or expansion of DN2 cells ( Figure 7B ). Despite the reduction in DN cells, the numbers of DP thymocytes were comparable in CD4-depleted and CD4-sufficient mATG-treated recipients at day 15 posttransplantation. Notably, the presence of peripheral CD4 T cells was required for optimal transition to SP CD4, but not SP CD8, T cells. As the thymic output of CD8 T cells early after mATG treatment is not affected by CD4 depletion, CD8 thymopoiesis alone is not sufficient for the rapid recovery of CD8 T cells. Thus, residual CD4 T cells are most likely to initiate optimal CD8 T cells recovery by inducing their early homeostatic proliferation and enhancing thymopoiesis at later time points.
Discussion
T cell depletion is commonly used as a part of treatment regimen in solid organ transplantation, graft-versus-host disease (GVHD) and autoimmunity (38) (39) (40) (41) (42) (43) (44) (45) (46) (47) (48) . Following the establishment of T cell lymphopenia, reconstitution of the peripheral T cell repertoire may be initiated through homeostatic proliferation and/or thymopoiesis (2, 7, 13, 49) . To date, the relative contribution of each pathway and the potential cross-talk between these two mechanisms of T cell reconstitution remain unknown. The goal of the current study was to test the role of the thymus in T cell reconstitution after mATG depletion in a mouse heart transplantation model. Major findings of our study include the following: (1) thymectomy delays T cell recovery in mATG-treated mice; (2) T cell recovery is only partially restored by the transplantation of a thymus, transfer of exogenous CD4 T cells, or CD40 ligation; and (3) depletionresistant peripheral CD4 T cells migrate into the thymus and their presence is associated with enhanced thymopoiesis. Even though CD4 and CD8 T cells were enriched for CD44 hi effector/memory phenotype after thymectomy, they were efficiently depleted by mATG and failed to rapidly reconstitute the host T cell repertoire in the absence of the thymus. These findings in mATG-treated heart allograft recipients are consistent with the previous report by Sener et al that na€ ıve and memory CD4 T cell reconstitution is delayed in thymectomized nontransplanted mice injected with mATG or anti-lymphocyte serum (50). Mature CD4 and CD8 T cells can reenter the thymus and may be involved in negative selection by regulating the expression of tissue-specific antigens in the thymus and direct killing of antigen-specific T cells (24, 25, (27) (28) (29) 51) . On the other hand, recirculating T cells have been implicated in thymocyte-positive selection (24) . The mechanisms by which recirculating CD4 T cells increase thymocyte maturation in mATG-treated allograft recipients ( Figure 6 ) remain to be determined in our future studies. One possibility is the production of interleukin (IL)-2 from recirculating CD4 T cells after reentry into the thymus. Mature T helper cells in the thymus can produce IL-2, and experiments using thymic cultures have shown that even low amounts of IL-2 can enhance the proliferation of DN cells by increasing the expression of IL-2 receptor (1, 52) . This possibility is plausible in our experiments because peripheral CD4 T cell depletion is associated with reduced thymopoiesis at the DN2 stage when thymocytes express high levels of CD25. This observation suggests that IL-2 produced by recirculating CD4 T cells may increase the proliferation of DN2 thymocytes leading to the overall increase in DN cells. In addition, thymus-infiltrating CD4 T cells may stimulate thymic resident cells to produce factors such as thymosin, thymulin, thymopoietin, IL-2, IL-15, or IL-7, that, will, in turn enhance thymopoiesis. Previous studies showed that these factors can be induced in thymic resident cells and promote thymic function (9, (53) (54) (55) (56) .
Our previous and current findings indicate that peripheral CD4 T cells influence both thymopoiesis and homeostatic proliferation in lymphopenic hosts. Clinical studies have shown that GVHD reduces thymopoiesis and that less thymic output is associated with more severe GVHD (13, 15) . Conversely, thymectomized mice injected with additional CD4 T cells in our study not only had better thymopoiesis but also demonstrated decreased antidonor T cell alloreactivity ( Figure 6 ). By facilitating thymopoiesis, we may have increased the proportion of antigen-inexperienced thymic-derived T cells in the periphery. Our results do not rule out the possibility that distinct populations of residual CD4 T cells mediate homeostatic proliferation versus thymopoiesis. In this case, detailed phenotypical and mechanistic studies may be needed to help us identify a specific population of CD4 T cells responsible for the enhanced thymopoiesis.
A comprehensive study of immune reconstitution in human transplant recipients treated with rabbit ATG by Gurkan and colleagues demonstrated evidence for contribution of both thymopoiesis and homeostatic proliferation (7) . Notably, the ATG administration induced thymic output of regulatory T cells in both pediatric and adult patients. It is possible that the enhanced thymopoiesis inhibits alloreactivity by increasing egress of regulatory T cells (Tregs) from the thymus to the periphery, as recently described (26) . While the analysis of Treg subsets in mATG-treated recipients was beyond the scope of the current study, it is possible that peripheral memory CD4 T cells facilitate thymic maturation of FoxP3 + Treg cells and that the enhanced immune regulation contributed to the lower anti-donor immune responses observed in recipients injected with tracer subsets of CD4 T cells ( Figure 6G ).
The ultimate goal of transplantation is to inhibit allograft rejection while preserving protective immunity. Despite the use of heavy immunosuppression with debilitating side effects, including opportunistic infections and cancer, the 5-year survival of solid organ transplants has not increased in the past decade (44, 57) . While lymphoablative induction therapies are beneficial in reducing the incidence of acute rejection episodes early after transplantation, they have minimal effects on long-term graft outcome (18, 35, 44) . Manipulating the repertoire of recovering T cells by targeting the recipient thymopoiesis after lymphoablation may be a valuable tool for managing the balance between transplant rejection and protective immunity. Our study demonstrates for the first time that the regulation of thymopoiesis and T cell homeostatic proliferation may be accomplished by targeting peripheral CD4 T cells. In particular, limiting homeostatic proliferation should diminish the proportion of descendants from preexisting memory T cells that are potentially pathogenic. On the other hand, facilitating thymopoiesis should enrich the resulting repertoire for diverse yet antigeninexperienced T cells thus diminishing preexisting alloreactivity while restoring recipient immunocompetence. These possibilities open a new avenue of investigation to achieve improved outcomes in transplant and autoimmunity patients undergoing lymphoablation.
